After Aerie Pharmaceuticals announced that it received early FDA approval of Rocklatan, JMP Securities analyst Donald Ellis said he expects the drug to be quickly adopted by physicians and patients given its best-in-class efficacy and once-a-day dosing. Many physicians are already prescribing Rhopressa + PGA and he would expect many to switch to Rocklatan alone, added Ellis, who keeps an Outperform rating and $75 price target on Aerie shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.